Whole-genome sequencing (WGS) brings comprehensive insights to cancer genome interpretation. To explore the clinical value of WGS, we sequenced 254 triple-negative breast cancers (TNBCs) for which associated treatment and outcome data were collected between 2010 and 2015 via the population-based Sweden Cancerome Analysis Network-Breast (SCAN-B) project (ClinicalTrials.gov ID:NCT02306096). Applying the HRDetect mutational-signature-based algorithm to classify tumors, 59% were predicted to have homologous-recombination-repair deficiency (HRDetect-high): 67% explained by germline/somatic mutations of BRCA1/BRCA2, BRCA1 promoter hypermethylation, RAD51C hypermethylation or biallelic loss of PALB2. A novel mechanism of BRCA1 abrogation was discovered via germline SINE-VNTR-Alu retrotransposition. HRDetect provided independent prognostic information, with HRDetect-high patients having better outcome on adjuvant chemotherapy for invasive disease-free survival (hazard ratio (HR) = 0.42; 95% confidence interval (CI) = 0.2-0.87) and distant relapse-free interval (HR = 0.31, CI = 0.13-0.76) compared to HRDetect-low, regardless of whether a genetic/epigenetic cause was identified. HRDetectintermediate, some possessing potentially targetable biological abnormalities, had the poorest outcomes. HRDetect-low cancers also had inadequate outcomes: ~4.7% were mismatch-repair-deficient (another targetable defect, not typically sought) and they were enriched for (but not restricted to) PIK3CA/AKT1 pathway abnormalities. New treatment options need to be considered for now-discernible HRDetectintermediate and HRDetect-low categories. This populationbased study advocates for WGS of TNBC to better inform trial stratification and improve clinical decision-making.
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Nature MediciNe influenced by sequencing depth: of cases sequenced to 30-fold depth, 3% failed, whereas 11% of cases failed when sequenced to 15-fold coverage. SCAN-B fresh-tissue procurement is fully integrated into routine clinical diagnostics across participating healthcare institutions 4 . Failure rates of ~3% thus provide true estimates of 30-fold WGS success in a clinical context, without preselection for tumor cellularity. The 15-fold coverage for clinical WGS is unlikely to be adequate.
Predicted somatic driver mutations, pathogenic germline mutations and somatic mutational signatures were obtained, together with regions of copy number loss, gain and loss of heterozygosity (LOH). These genomic features in the SCAN-B TNBC cohort were comparable to a previously reported WGS cohort 8 (Extended Data 2). To assess the additional benefits of WGS-based stratification, we applied a mutational-signature-based algorithm, HRDetect 9 , designed to detect 'BRCA'ness or homologous-recombination-repair deficiency (HRD), using default breast-cancer-specific parameters. More than half of TNBCs (58.6%) were classified as HRDetect-high (exceeding a predefined score of 0.7, predictive of BRCA1/BRCA2deficiency 9 ). A total of 35.9% were classified as HRDetect-low Letters Nature MediciNe (score <0.2) and 5.5% fell within an HRD-intermediate category (score 0.2-0.7) ( Fig. 2a ).
To compare customary breast cancer stratification methods with HRDetect, we examined age, grade and gene expression phenotypes (for example, PAM50 10 , CIT 11 , IC10 12 , TNBCtype 13 ) in this cohort. HRDetect-high classification was enriched in expected subgroups such as young patients (88.5% of women <50 years), high-grade tumors and a basal-like expression subtype (PAM50 basal-like 10 , CIT basal-like 11 , IC10 IntClust 10 12, 14 and TNBCtype basal-like 1 13 ) (Supplementary Table 1 and Fig. 2a ). However, HRDetect-high scores were also observed in tumors with ER-staining (62.1% of cases with 1-10% ER-staining intensity), in middle-aged patients (58% of women aged 50-70 years were HRDetect-high) and older patients (>70 years, 36.4% HRDetect-high cases), as well as in tumors with non-basallike gene expression profiles ( Supplementary Table 1 ). Consequently, the HRD phenotype identified by HRDetect is enriched for, but not restricted to, typical basal-like tumors characteristic of young patients in TNBC. The corollary is also true-expression-based profiling (for example, PAM50) and integrative clusters 12, 14 are not adequately able to discriminate HRDetect groups, suggesting that HRDetect provides a novel, independent angle to TNBC stratification.
Previously, substitution signature 3 and specific patterns of copy number aberrations (CNAs, 'genomic scars') have been used to infer an HRD phenotype 15, 16 . However, choosing a signature 3 cutoff is challenging, as this signature has a featureless, flat profile, where mutations are often mis-assigned. The CNA-based 'HRD assay' has a designated cutoff of 42 (ref. 15 ). When compared with HRDetect as reference, the 'HRD assay' has a false negative rate of 13%, and 16% of CNA-based HRD-high cases were false positives. HRDetect is therefore more specific than current substitution signature and CNA approaches, while extending identification of HRD to a wider set of samples and revealing tumors that are likely inactivated by ways other than classical mechanisms ( Fig. 2b) .
Next, to comprehensively understand the causes of HRDetecthigh scores, we examined germline and somatic mutation status of BRCA1, BRCA2, a set of 163 additional HR-related or breast cancer susceptibility genes (Supplementary Data Table) , as well as the status of the remaining wild-type parental allele in all samples. Systematic promoter hypermethylation by pyrosequencing of BRCA1 and RAD51C was also performed.
Of 139 HRDetect-high cases, 29 (21%) had confirmed biallelic loss of BRCA1 or BRCA2 (that is, 20 germline and 9 somatic with LOH of the wild-type parental allele) and 55 (40%) had BRCA1 hypermethylation with loss of the other parental allele in ∼90% of cases ( Fig. 2a , note one case with concurrent BRCA2 biallelic alteration and BRCA1 hypermethylation). There were no instances of a dominantly inherited 5′ untranslated region (UTR) variant causing methylation-associated BRCA1 silencing 17 .
Five tumors had pathogenic germline PALB2 variants, three cases with a c.509_510delGA variant (two biallelic, one monoallelic), one c.3239_3240delAA variant, one c.1039 G>T variant. Four had wild-type allele inactivation through somatic pathogenic mutation in three cases and LOH in one instance. Five RAD51C hypermethylation cases were also observed with concomitant marked downregulation of RAD51C mRNA expression (Wilcoxon-test P = 0.0001). Intriguingly, the four biallelic PALB2 and five RAD51C cases (together comprising 6.5% of HRDetect-high cases) consistently showed a BRCA2null phenotype 8 including elevated substitution signature 3, elevated rearrangement signatures 2 and 5, and no rearrangement signature 3 (Figs. 2a and 3a-d and Supplementary Data Table) , evidenced also by principal component analysis (PCA) of HRDetect components (Fig. 3e ). PALB2, RAD51C and BRCA2 are involved in a complex that stimulates strand invasion of the RAD51 nucleoprotein filament 18, 19 , a critical step in HR-related repair. Thus, their BRCA2-like profiles may be explained by these molecular relationships.
The causes for HRDetect-high scores in the remaining 46 (33%) samples were unclear. Six were monoallelic for BRCA1/BRCA2 and had low tumor cellularity possibly preventing a correct call of LOH for the parental allele. RAD51 and PALB2 pyrosequencing did not reveal positive findings. Mobile element analysis for 11 HR genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MRE11, NBN, PALB2, RAD51C, RAD51D) identified a germline SINE-VNTR-Alu (SVA) retrotransposon 1.8 kb downstream of the first coding exon of BRCA1 in one patient, PD35958a. This specific mobile element has not been reported in the 1,000 genomes dataset. Moreover, wildtype allele LOH was noted and BRCA1 expression was markedly reduced in this tumor. SVA elements have been reported as diseasecausing 20 , but not in BRCA1. Thus, this observation may indicate a potential novel mechanism of germline BRCA1 abrogation.
Fourteen new pathogenic germline BRCA1/BRCA2 variants were identified, in addition to the 12 hitherto known variants, raising clinical genetic counselling implications. In Sweden, re-contacting patients/families based on BRCA1/BRCA2 incidental findings has been perceived positively 21 supporting the added value that tumordirected WGS brings to family counselling.
To seek distinguishing features between different HRDetect groups, we examined driver alterations. HRDetect-high and HRDetect-intermediate cases tended toward more driver amplifications (for example, MYC and MCL1) than HRDetect-low (Extended Data 3). Eight substitution/indel driver genes were enriched, albeit non-discriminatory between groups (TP53, PTEN, ARID1B, MLLT4 for HRDetect-high, PIK3CA and AKT1 for HRDetect-low and RB1 and FBXW7 for HRDetect-high and HRDetect-intermediate) (chisquared test, P < 0.05, Extended Data 3). Of interest, PTEN driver mutations and activating PIK3CA and AKT1 mutations are differently enriched between HRDetect-high and HRDetect-low groups: 29% versus 14% for PTEN, 2.2% versus 25% for PIK3CA, and 0.7% versus 7.1% for AKT1 for HRDetect-high versus HRDetect-low, respectively. Thus, PIK3CA/AKT1/PTEN pathway dysregulation is not restricted to a particular HRDetect group. This has potential 11 , integrative cluster 10 (IC10) and TNBCtype are represented by pie charts. Intermediary samples are excluded due to low numbers. CIT subtypes: mApo, molecular apocrine. IC10 subtypes 12 : cl (IntClust) 10 corresponding to basal-like tumors by other subtyping schemes. TNBCtype subtypes 13 : BL1, basal-like 1; BL 2, basal-like 2; IM, immunomodulatory; M, mesenchymal; MSL, mesenchymal stem-like; LAR, luminal androgen receptor; UNS, uncertain. b, Proportions of mutational signature 3 (in tumors with >20 events) and copy number-derived HRD scores according to ref. 15 across subgroups defined first by HRDetect class (-low, -intermediate and -high), where the HRDetect-high subgroup is further divided into whether BRCA1/BRCA2 was inactivated by a germline mutation, somatic mutation or promoter hypermethylation, or no mutation was identified. Right axes in boxplots show the number of patients in each group. Boxplot elements: center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range.
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implications for patient selection in clinical trials using PI3K-AKT-mTOR pathway agents, as mis-stratifying patients based on single mutations may affect clinical trial success.
To investigate whether HRDetect groups were simply genetic portraits of traditional transcriptional TNBC subgroups, we performed unsupervised group discovery and machine learning based HRDetect categorizes tumors differently to customary TNBC classifiers. We thus evaluated whether HRDetect's signature-based stratification had prognostic potential. TNBC patients that did not receive adjuvant treatment due to age and/or poor performance status were considered a particular subgroup and assessed separately (Supplementary Table 2 ). For these patients, there were no differences observed in overall survival (OS), invasive disease-free survival (IDFS) or distant relapse-free interval (DRFI) between HRDetect-high and HRDetect-low categories (log-rank P > 0.05).
In distinct analyses of patients that received standard-of-care adjuvant chemotherapy (ACT) (typically fluorouracil, epirubicin and cyclophosphamide (FEC) ± docetaxel, Supplementary Data Table) , patients with HRDetect-high tumors had significantly improved IDFS and DRFI (log-rank P = 0.009 and P = 0.01) compared to those with HRDetect-low tumors (Fig. 4a,b ). An improved OS was also observed (log-rank P = 0.06, Fig. 4c ), albeit nonsignificant, likely because of the limited follow-up interval. This suggests that TNBC patients with HRDetect-high scores have a higher degree of chemosensitivity than HRDetect-low cases and are worth identifying.
Strikingly, chemotherapy-treated HRDetect-low patients had a similar IDFS to patients that did not receive ACT, in spite of superior fitness and lower age of diagnosis (85%, ≤70 years) ( Fig. 4d,e ). Soberingly, this suggests that HRDetect-low cases are deriving limited benefit from the current standard of care, warranting a reappraisal of systemic therapies for this now-identifiable subgroup with poor outcome.
To test the independent prognostic value of HRDetect in patients receiving adjuvant chemotherapy, we performed multivariable Cox regression, adjusting for tumor size (≤20 mm, >20 mm), patient age (<50, ≥50 years), tumor grade (1, 2, 3) and lymph node status (N0, N+). We found that HRDetect classification among chemotherapy-treated patients provided independent prognostic information favoring a better outcome in HRDetect-high cases than in HRDetect-low cases, for IDFS (HR = 0.42, 95% CI = 0.20-0.87) and DRFI (HR = 0.31, CI = 0.13-0.76). Although not significant for OS (HR = 0.46, CI = 0.19-1.13), this implies a potential effect with longer follow-up time (∼60% of the chemotherapy-treated cases had ≤5 years of follow-up).
Notably, within the HRDetect-high group, we observed no difference in patient outcomes (OS, IDFS and DRFI) between cases with confirmed BRCA1/BRCA2 loss and cases where it was not possible to confirm genetic/epigenetic abrogation of these genes (logrank P = 0.79, 0.51 and 0.67, respectively, Fig. 4f ). Lending further credence, survival analysis excluding known BRCA1/BRCA2 cases showed that HRDetect-high classification remained significantly associated with improved IDFS in remaining patients (log-rank P = 0.008, multivariable Cox regression HR = 0.41, CI = 0.19-0.91, P = 0.03). BRCA1/BRCA2 abrogated status was next added as a covariate to the multivariable Cox regression. HRDetect classification persisted as a meaningful independent positive prognostic indicator for IDFS (HR = 0.38, CI = 0.17-0.85, P = 0.02). This strengthens the argument that, even in the absence of confirmation of the genetic/epigenetic aetiology, the mutational signature-based approach is capable of predicting potential clinical benefit for ACT. Critically, it expands the number of TNBC patients eligible for treatment strategies targeting DNA repair mechanisms such as poly (ADP-ribose) polymerase (PARP) inhibitors 22 .
We note that four HRDetect-low patients (4.7%) had mismatchrepair deficient (MMRd) tumors 23 (Extended Data 5). One occurred in association with HRD. Despite a lack of genetic/epigenetic confirmation of MMR abrogation in these cases, independent analyses by protein IHC confirmed tumor-cell-specific loss of MLH1 and PMS2 expression in all cases (Extended Data 5). This is of particular interest, as checkpoint inhibitors have been FDA-approved for MMRd in the metastatic setting, irrespective of tumor origin, emphasizing the therapeutically valuable incidental insights that can be obtained via a WGS-based approach.
Finally, we explored the HRDetect-intermediate cohort (scores 0.2-0.7, n = 13, 5.5%). We noted that 83.5% of HRDetect-high tumors had scores exceeding 0.99, and nearly all were BRCA1/BRCA2-null tumors. Additionally, based on mutational, indel and rearrangement signature patterns, cases with HRDetect-intermediate scores had different characteristics ( Fig. 2a) .
We thus broadened the HRDetect-intermediate category to scores between 0.1 and 0.9 (n = 32). Driver alterations and mutational signatures for the redefined groups were examined in a new analysis (Extended Data 6). The broadened HRDetect-intermediate group had a high prevalence of driver amplifications (75%, 24/32 cases) and harbored 47% of all CCNE1 amplifications. CCNE1 was the most enriched amplification, constituting 25% of all amplifications in this new intermediate group. This is interesting, as CCNE1 is implicated in oncogene-induced replicative stress 24, 25 . The intermediate category is also enriched for hypermutators of a rearrangement signature of long tandem-duplications (RS1) (where RS1 is predominant, exceeding 100 RS1 rearrangements) 26 . This pattern has been shown in prostate cancer 26 , and also in ovarian cancer 27, 28 associated with CDK12 mutations. CCNE1 and CDK12 over-expression has been shown to deregulate cell cycle progression and disrupt DNA replication during S phase in vitro 29, 30 . Recently, inhibitors of The circos plot is structured as follows (from the outermost rings heading inwards): the karyotypic ideogram outermost; base substitutions, plotted as rainfall plots (log 10 intermutation distance on radial axis; ring with short green lines, insertions; ring with short red lines, deletions; major copy number allele ring (green, gain), minor copy number allele ring (red, loss), central lines represent rearrangements (green, tandem duplications; red, deletions; blue, inversions; gray, interchromosomal events). b, Circos plot of a BRCA2 germline altered TNBC case classified as HRDetect-high. c, Circos plot and mutational signatures of a PALB2 biallelic altered TNBC case classified as HRDetect-high, where the histograms below show the distribution of substitution signatures (left), rearrangement signatures (right) and deletions and insertions (center) as defined in ref. 8 . Del, deletion. d, Circos plots and mutational signatures of a RAD51C hypermethylated TNBC case classified as HRDetect-high. e, PCA of the six normalized HRDetect components 9 for the 237 TNBC cases annotated by their BRCA1, BRCA2, PALB2 or RAD51C status. The plot displays PCA components 1 and 3 (accounting for 92.3% of variation across the six HRDetect components), showing the separation of biallelic BRCA2, biallelic PALB2 and RAD51C hypermethylated cases into a common sector (light gray), indicating the similarities of HRDetect features.
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replication stress response such as Wee1 kinase inhibitors, ATR inhibitors and CHK1-inhibitors were developed to target tumors with hallmarks of replication stress 31 , and CCNE1 overexpression was reported to sensitize TNBCs to these compounds 32 This population-based study of TNBC in a routine diagnostic setting demonstrates what can be revealed by WGS. We surmise that it is valuable to identify HRDetect status, whether high, intermediate or low. All groups are informative. Combinations of targeted-sequencing, microsatellite instability (MSI) assays and CNA approaches may be used increasingly. However, the value of holistic WGS as a single assay is reinforced when we consider three matters. First, patients may be mis-classified based on individual mutations. For example, we show that PIK3CA/AKT1/PTEN mutations identified through targeted sequencing are differentially enriched in HRDetect categories, with different survival likelihoods. Using mutations alone to stratify patients should thus be carefully considered in clinical trials. Second, it is possible to identify poor responders to the current standard of care that cannot be detected by any other method. The HRDetect-low category has many more patients than would be detected by binary PIK3CA/AKT1/PTEN targeted assays alone. These limited assays will also not identify the HRDetect-intermediate category, an interesting now-detectable subset in which to explore alternative therapeutic strategies. Third, limited sequencing assays will miss the substantial proportion of tumors with HRD signatures that do not have genetic/epigenetic drivers but are predicted to have good outcomes. In short, this study argues for WGS to improve TNBC patient stratification. 
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Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0582-4.
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Methods Ethics approval and consent to participate. The SCAN-B study was approved by the Regional Ethical Review Board in Lund, Sweden (applicable registration numbers 2009/658, 2015/277, 2016/742, 2018/267 and 2019/01252 for this study). All patients provided written informed consent prior to enrolment.
Patient cohort. In Sweden, the definition of TNBC is a tumor with ≤10% of cells with IHC-staining for ER and PR (thus including tumors with 1-10% stained cells) and an IHC HER2-staining score of <2, or for patients with IHC 2+, a nonamplified ISH status. During the period 1 September 2010 to 31 March 2015, 408 patients were diagnosed with TNBC (localized or advanced disease with specified treatment status) in the Skåne healthcare region in southern Sweden, based on data from the Swedish national breast cancer quality registry, NKBC (Fig. 1) . In total, 340 of these patients were enrolled in the SCAN-B study 4, 5 (ClinicalTrials.gov ID NCT02306096), a prospective, observational, population-based cohort study, from which 254 patients with concurrent RNAseq were selected for extensive clinical review and WGS. Of the reviewed cases, 153 (60%) patients were eligible for OS/ IDFS survival analysis after standard-of-care adjuvant chemotherapy (FEC-based (combination of 5-fluorouracil, epirubicin and cyclophosphamide) ± a taxane in 96% of cases) according to national guidelines. Of these (irrespective of clinical endpoint status), 41% had ≥5 years of follow-up, 25% 4-5 years, 31% 2-4 years and 4% <2 years of follow-up. Of the 153 patients, 148 (97%) were eligible for relapse analysis, of which 20% developed a relapse of some type (loco-regional or distant). Remaining cases received either neoadjuvant treatment, no adjuvant treatment or were not treated in an adjuvant context (for example, metastatic disease at diagnosis). As part of routine oncogenetic clinical screening, 49 of 254 recruited patients were previously screened for pathogenic germline variants in BRCA1 and BRCA2, with 12 positive findings (nine BRCA1 and three BRCA2 carriers). Patient cohort characteristics, enrolled SCAN-B patients, WGS analyzed SCAN-B patients and WGS analyzed SCAN-B treatment subsets are described in Supplementary  Table 2 . Individual patient characteristics are provided in the Supplementary Data Table. Tissue sampling, DNA and RNA extraction. Fresh tumor samples preserved in RNAlater (Qiagen) were obtained in conjunction with routine clinical sampling by a diagnostic pathologist in regional pathology departments 4 . RNA and DNA were extracted using the Qiagen Allprep extraction kit (Qiagen) as described in ref. 5 . DNA from whole blood was extracted by the Labmedicin Skåne Biobank.
Whole-genome sequencing. WGS of TNBCs were performed using Illumina sequencing technology to achieve average coverage of 15-30-fold depth as previously described in matched tumor-normal samples 8 . Each patient was sequenced only once. Patients that received ACT were primarily selected for 30-fold coverage, whereas untreated patients were sequenced to 15-fold depth. WGS data quality, basic data analysis, variant calling, mobile element analysis and HRD classification by the HRDetect algorithm were performed as outlined in refs. 8, 9 and the Supplementary Information. HRDetect classification was verified for known BRCA1/BRCA2-deficient cases versus tumor cellularity by WGS or pathology estimation for both 30-fold and 15-fold sequencing depth (Extended Data Fig. 7 ) to demonstrate that there was no systematic bias as a result of sequencing coverage or tumor cellularity.
DNA promoter methylation analysis. DNA promoter hypermethylation analysis of bisulfite-treated DNA for specific CpG promoter sites in BRCA1, RAD51C, RAD51 and PALB2 was performed as described in the Supplementary Information.
Gene expression analyses.
Gene expression profiling of all TNBCs was performed using RNA sequencing as described in ref. 5 , and data have been reported elsewhere 33 . Molecular subtype classification according to PAM50 (by AIMS) 10 , IC10 12 , CIT 11 and reported TNBC subtypes (TNBCtype) 13, 34 , unsupervised clustering and machine learning based supervised classification were performed as described in the Supplementary Information.
Statistical analyses. Survival analyses were performed in R (version 3.3.0) using the survival package with OS, IDFS or DRFI as endpoints, defined according to the STEEP criteria 35 (see Supplementary Information for endpoint definitions and analysis exclusion criteria). Survival curves were compared using Kaplan-Meier estimates and the log-rank test. Hazard ratios were calculated through univariable or multivariable Cox regression using the coxph R function. Harrell's C-index was computed using the dynpred R package. Statistical comparisons between groups were performed using Wilcoxon's or Kruskal-Wallis tests for numerical values or the chi-squared test for ordinal values. All P values reported from statistical tests are two-sided if not otherwise specified.
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Extended Data Fig. 1 | Sweden Cancerome Analysis Network -Breast (SCAN-B) . In the Skåne healthcare region (Region Skåne) four main hospitals are participating in the SCAN-B study: Lund, Malmö, Helsingborg and Kristianstad. a, SCAN-B overall enrolment rate at all participating hospitals, including Skåne healthcare region, during the period 1 September 2010 to 31 March 2015, corresponding to the same time period from which the TNBC cases in the current study were selected. The statistics are restricted to the seven hospitals where enrolment was operational from the start in 2010. b, Overall accrual rate per quarter of a year (Q1-Q4) for the SCAN-B study since the start in 2010 Q4 up until 2018 Q1. The red line corresponds to the cumulative number of enrolled patients, reaching nearly 12,000 in 2018 Q1. c, Illustration of the population-based nature of the SCAN-B study for primary resectable breast cancer. Based on data from the national breast cancer quality registry in Sweden (NKBC), a background population of primary resectable breast cancers from the entire SCAN-B catchment region during the period 1 September 2010 to 31 March 2015 was identified (same time period from which the TNBC cases in the current study were selected), comprising 8,587 patients. Of these 8,587 patients, 5,417 were enrolled in SCAN-B, with 3,520 patients having RNA sequencing data passing basic quality criteria. The lower panels demonstrate the clinicopathological characteristics of the different subgroups in the consort diagram, demonstrating the representativity of the end RNA sequencing cohort compared to all enrolled SCAN-B patients and the total patient population in the catchment region. Note that the RNA sequencing cohort has a slightly lower inclusion of smaller tumors, due to the fact that the SCAN-B tissue sampling is performed by a pathologist after enough tissue has been secured for routine diagnostics. 
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n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data collection
Whole genome sequencing data from Illumina X10 machines generated 150 base pair paired-end reads. Paired-end reads were aligned to the reference human genome (GRCh37) using Burrows-Wheeler Aligner, BWA (v0.7.15) to generate raw sequencing data.
Collection and basic processing of RNA sequencing data from SCAN-B has been previously described (Saal et al. Genome Medicine 2015) . DNA methylation data from pyrosequencing was analyzed using the PyroMark software included with the pyrosequencing instrument (Qiagen).
Data analysis
